Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

INTRODUCTION: Improvements in glycemic control and hepatic function are clinically important goals in the treatment of patients with type 2 diabetes mellitus (T2DM) complicated by hepatic dysfunction. The favorable effects of the sodium–glucose co-transporter inhibitor luseogliflozin on hepatic dysf...

Descripción completa

Detalles Bibliográficos
Autor principal: Seino, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947107/
https://www.ncbi.nlm.nih.gov/pubmed/33594581
http://dx.doi.org/10.1007/s13300-021-01014-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947107/
https://www.ncbi.nlm.nih.gov/pubmed/33594581
http://dx.doi.org/10.1007/s13300-021-01014-0

Ejemplares similares